Journal
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Volume 209, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jsbmb.2021.105848
Keywords
Estrogen receptor; Breast cancer; Endocrine therapy; Degradation
Funding
- National Natural Science Foundation of China [81102380]
- Science Technology Department of Zhejiang Province [1922D]
- Health and Family Planning Commission of Zhejiang Province [2021KY125, XKQ-01001]
Ask authors/readers for more resources
ERα plays a key role in breast cancer and has been a target for endocrine therapy, but long-term treatment with AIs or SERMs may lead to drug resistance and increase the risk of uterine cancer. Therefore, novel anti-breast cancer drugs based on different mechanisms of action, especially through selective degradation of ER, have attracted significant attention.
Estrogen receptor subtype ? (ER?) plays key roles in breast cancers, and has been a target for endocrine therapy for a long time. Unfortunately, long-term treatment by Aromatase Inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMs) could cause drug resistance and also would increase the risk for uterine cancer. Therefore, novel anti-breast cancer drugs based on different mechanisms of action have received significant attention, especially through the strategies of selective degradation of ER. In this article, the latest research progress of selective targeting ER for degradation, including Selective ER Downregulators (SERDs), Proteolysis Targeting Chimaeras (PROTACs) and other techniques, was reviewed, and the applications and problems to be solved were prospected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available